Zoetis Inc (ZTS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Zoetis Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 11 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 77.30 $ — 6% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 44.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 20
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6.86 | 6.76 – 6.95 | 9,753 | 7.0% | 17 |
| 12/31/2027 | 7.39 | 7.06 – 8.03 | 10,148 | 7.7% | 19 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 1.84 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.29 | 12.90 | 2,317 | 4.70 | 25.10 | 905 | 689 |
| 2025: Q1 | 1.41 | 7.90 | 2,220 | 1.40 | 28.40 | 587 | 438 |
| 2025: Q2 | 1.61 | 17.80 | 2,460 | 4.20 | 29.20 | 486 | 308 |
| 2025: Q3 | 1.63 | 8.20 | 2,400 | 0.50 | 30.00 | 938 | 805 |
| 2025: Q4 | 1.37 | 6.70 | 2,387 | 3.00 | 25.30 | 893 | 732 |
| 2026: Q1 | 1.42 | 1.00 | 2,262 | 1.90 | 26.60 | 401 | 291 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 4,888 | 1,404 | 821 | 1.65 | 713 | 1,499 | 7,649 |
| 2017 | 5,307 | 1,727 | 864 | 1.75 | 1,346 | 1,786 | 8,586 |
| 2018 | 5,825 | 1,881 | 1,428 | 2.93 | 1,790 | 2,185 | 10,777 |
| 2019 | 6,260 | 2,018 | 1,500 | 3.11 | 1,795 | 2,708 | 11,545 |
| 2020 | 6,675 | 2,269 | 1,638 | 3.42 | 2,126 | 3,769 | 13,609 |
| 2021 | 7,776 | 2,803 | 2,037 | 4.27 | 2,213 | 4,543 | 13,900 |
| 2022 | 8,080 | 2,928 | 2,114 | 4.49 | 1,912 | 4,405 | 14,925 |
| 2023 | 8,544 | 3,069 | 2,344 | 5.07 | 2,353 | 4,997 | 14,286 |
| 2024 | 9,256 | 3,392 | 2,486 | 5.47 | 2,953 | 4,770 | 14,237 |
| 2025 | 9,467 | 3,597 | 2,673 | 6.02 | 2,904 | 3,331 | 15,467 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Zoetis Inc. entdeckt, entwickelt, fertigt und kommerzialisiert Medikamente, Impfstoffe, Diagnostikprodukte und -dienste, Biogeräte, Gentests und Präzisionslösungen für die Tiergesundheitsbranche in den USA und international.
| Employees | 14,500 |
|---|---|
| Headquarters | Parsippany, NJ |
| Address | 10 Sylvan Way, 07054 Parsippany, United States |
| Phone | 973 822 7000 |
| Website | zoetis.com |
| IPO Date | 1. Feb 2013 |
| ISIN | US98978V1035 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Kristin C. Peck | CEO & Director | 1971 |
| Wetteny N. Joseph CPA | Executive VP & CFO | 1972 |
| Roxanne Lagano | Executive VP, General Counsel & Corporate Secretary | 1965 |
| Robert J. Polzer Ph.D. | Scientific Advisor | 1969 |
| Jamie Brannan | Executive VP & Chief Commercial Officer | 1973 |
| Keith Sarbaugh | Executive VP & Chief Digital and Technology Officer | 1979 |
| Steven Frank | Vice President of Investor Relations | – |
| Julie A. Fuller | Executive VP, Chief Human Resources Officer & Global Operations | 1973 |
| Abhay U. Nayak | Executive VP & President of U.S. Commercial Operations | 1988 |
| Jeannette Ferran Astorga | Executive VP of Corporate Affairs & Chief Sustainability Officer | 1976 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.